JP2020516244A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516244A5
JP2020516244A5 JP2019554630A JP2019554630A JP2020516244A5 JP 2020516244 A5 JP2020516244 A5 JP 2020516244A5 JP 2019554630 A JP2019554630 A JP 2019554630A JP 2019554630 A JP2019554630 A JP 2019554630A JP 2020516244 A5 JP2020516244 A5 JP 2020516244A5
Authority
JP
Japan
Prior art keywords
seq
sequence
disease
composition according
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019554630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516244A (ja
JP7296321B2 (ja
Filing date
Publication date
Priority claimed from GBGB1705484.2A external-priority patent/GB201705484D0/en
Application filed filed Critical
Publication of JP2020516244A publication Critical patent/JP2020516244A/ja
Publication of JP2020516244A5 publication Critical patent/JP2020516244A5/ja
Application granted granted Critical
Publication of JP7296321B2 publication Critical patent/JP7296321B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019554630A 2017-04-05 2018-03-28 神経変性障害または脳卒中の治療に用いる遺伝子構築物 Active JP7296321B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1705484.2A GB201705484D0 (en) 2017-04-05 2017-04-05 Genetic construct
GB1705484.2 2017-04-05
PCT/GB2018/050824 WO2018185468A1 (en) 2017-04-05 2018-03-28 Genetic construct for use in the treatment of neurodegenerative disorder or stroke

Publications (3)

Publication Number Publication Date
JP2020516244A JP2020516244A (ja) 2020-06-11
JP2020516244A5 true JP2020516244A5 (https=) 2021-05-06
JP7296321B2 JP7296321B2 (ja) 2023-06-22

Family

ID=58682577

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019554630A Active JP7296321B2 (ja) 2017-04-05 2018-03-28 神経変性障害または脳卒中の治療に用いる遺伝子構築物

Country Status (14)

Country Link
US (1) US20200046850A1 (https=)
EP (1) EP3606546B1 (https=)
JP (1) JP7296321B2 (https=)
KR (1) KR102616629B1 (https=)
CN (1) CN110809476B (https=)
AU (1) AU2018248651B2 (https=)
CA (1) CA3058549A1 (https=)
ES (1) ES2881176T3 (https=)
GB (1) GB201705484D0 (https=)
MX (1) MX2019012000A (https=)
PL (1) PL3606546T3 (https=)
PT (1) PT3606546T (https=)
RU (1) RU2757932C2 (https=)
WO (1) WO2018185468A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3687580A1 (en) * 2017-09-27 2020-08-05 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
AU2019407921A1 (en) * 2018-12-19 2021-06-10 Versameb Ag RNA encoding a protein
JP7524158B2 (ja) 2019-03-04 2024-07-29 公益財団法人東京都医学総合研究所 Trk断片をコードする核酸構築物、及びその利用
AU2020248099A1 (en) * 2019-03-27 2021-10-07 Sigilon Therapeutics, Inc. Compositions, devices and methods for treating Fabry disease
GB202004832D0 (en) * 2020-04-01 2020-05-13 Instituto De Medicina Molecular Faculdade De Medicina Univ De Lisboa Therapeutic agaents, pharmaceutical compositions, and associated biomarkers
US20240050524A1 (en) * 2020-12-18 2024-02-15 Baylor College Of Medicine Delivery of abeta variants for aggregation inhibition
CN114933657B (zh) * 2021-08-25 2024-02-02 上海交通大学医学院 神经生长因子突变体重组蛋白及其应用
CN118256562A (zh) * 2022-12-26 2024-06-28 科辉智药(深圳)新药研究中心有限公司 一种用于中枢神经系统疾病治疗的基因序列构建体及其应用
AU2024214634A1 (en) 2023-02-02 2025-06-26 Quethera Limited Recombinant adeno-associated virus vector
EP4413993A1 (en) * 2023-02-10 2024-08-14 Dompe' Farmaceutici S.P.A. Method of obtaining recombinant human brain-derived neurotrophic factor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2588221C (en) * 1999-06-08 2013-07-09 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20030124095A1 (en) * 2001-12-31 2003-07-03 Regents Of The University Of California Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
US9265843B2 (en) * 2008-03-27 2016-02-23 The Ohio State University Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor
EP3165537A1 (en) * 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
HK1210211A1 (en) * 2012-03-15 2016-04-15 科纳公司 Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct

Similar Documents

Publication Publication Date Title
JP2020516244A5 (https=)
RU2019131098A (ru) Генетическая конструкция для применения при лечении нейродегенеративного нарушения или инсульта
JP2018535696A5 (https=)
HRP20211407T1 (hr) Genetska konstrukcija
JP2025063261A (ja) Aavカプシドの向性の再指向化
AU2022259813A1 (en) Novel adeno-associated virus capsid proteins
JP2021516046A5 (https=)
JP2019141076A5 (https=)
IL320714A (en) Gene therapy for limb-girdle muscular dystrophy type 2c
JP2009513162A5 (https=)
JP2020527333A5 (https=)
CA2627200A1 (en) Novel activin receptor and its uses in treating metabolic disorders
TW202005978A (zh) 新穎肝靶向腺相關病毒載體
FI3589730T3 (fi) Kladin f adenoassosioitunut virus (aav) -vektori ja sen käyttötapoja
JP2020510429A5 (https=)
RU2017115477A (ru) Полинуклеотиды aadc для лечения болезни паркинсона
JP2021528983A5 (https=)
JP2023021996A (ja) ウイルスカプシドタンパク質組成の分析方法
RU2018129159A (ru) Рекомбинантные aav векторы, экспрессирующие остеопротективные гены, включая has2 и лубрицин, пригодные при лечении остеоартрита и сходных заболеваний суставов у млекопитающих
JP2021534755A5 (https=)
JP2022553307A5 (https=)
JP2021525245A5 (https=)
JP2024527313A5 (https=)
JP2023553005A5 (https=)
WO2008124015A1 (en) Methods for purifying adeno-associated virus virions